Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US1143401024
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG000DX9JV7
AZTA
Azenta Inc
GICS: Information Technology · SECTOR: EQTY · SUB-SECTOR: Medical Instruments & Supplies · THEMEFOLIO: $HLTH
NAME
Azenta Inc
ISIN
US1143401024
TICKER
AZTA
MIC
XNAS
REUTERS
AZTA.OQ
BLOOMBERG
AZTA US
Fr., 15.05.2026       Azenta
US1143401024

NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Azenta, Inc. ("Azenta" or the "Company") (NASDAQ: AZTA).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Azenta
Charts & Research Termsheets Terminal
Permalink
Mi., 13.05.2026       Azenta
US1143401024

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Azenta, Inc. (“Azenta” or the “Company”) (NASDAQ: AZTA) investors concerning the Company’s possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON AZENTA,...
Zur Nachricht
Azenta
Charts & Research Termsheets Terminal
Permalink
Mi., 13.05.2026       Azenta
US1143401024

Law Offices of Howard G. Smith announces an investigation on behalf of Azenta, Inc. (“Azenta” or the “Company”) (NASDAQ: AZTA) investors concerning the Company’s possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN AZENTA, INC. (AZTA), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAI...
Zur Nachricht
Azenta
Charts & Research Termsheets Terminal
Permalink
Mi., 13.05.2026       Azenta
US1143401024

New York, New York--(Newsfile Corp. - May 13, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Azenta, Inc. ("Azenta, Inc.") (NASDAQ: AZTA) concerning potential violations of the federal securities laws.On February 4, 2026, CEO John Marotta told investors Azenta was "entering the year well positioned for c...
Zur Nachricht
Azenta
Charts & Research Termsheets Terminal
Permalink
Mi., 13.05.2026       Azenta
US1143401024

Azenta, Inc. reported GAAP results revealing a $160.8 million net loss driven by a $149 million goodwill impairment. NEW YORK, May 13, 2026 /PRNewswire/ -- Azenta, Inc. (NASDAQ: AZTA) investors lost money when the stock dropped sharply after the Company's Q2 FY 2026 earnings revealed a $160.8 million GAAP net loss -- largely driven by a non-cash...
Zur Nachricht
Azenta
Charts & Research Termsheets Terminal
Permalink
Di., 12.05.2026       Azenta
US1143401024

The Law Offices of Frank R. Cruz announces an investigation of Azenta, Inc. (“Azenta” or the “Company”) (NASDAQ: AZTA) on behalf of investors concerning the Company’s possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON AZENTA, INC. (AZTA), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR L...
Zur Nachricht
Azenta
Charts & Research Termsheets Terminal
Permalink
Sa., 09.05.2026       Azenta
US1143401024

The law firm of Kirby McInerney LLP is investigating potential claims against Azenta, Inc. (“Azenta” or the “Company”) (NASDAQ:AZTA). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION...
Zur Nachricht
Azenta
Charts & Research Termsheets Terminal
Permalink
Di., 05.05.2026       Azenta
US1143401024

FY'26 total reported revenue from continuing operations to range between approximately $603 to $621 millionFY'26 organic revenue is now expected to range from down approximately 2% to up 1%, compared to prior guidance of 3% to 5% growthFY'26 Adjusted EBITDA margin is now expected to range from down approximately 125 basis points to flat, compared...
Zur Nachricht
Azenta
Charts & Research Termsheets Terminal
Permalink
Mi., 29.04.2026       Azenta
US1143401024

BURLINGTON, Mass., April 29, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal second quarter 2026 earnings which ended on March 31, 2026, on Wednesday, May 6, 2026, before the market opens.The Company will host a conference call and live webcast to discuss its financial results on the same day, Wednesday, May 6, 2026, at 8:30...
Zur Nachricht
Azenta
Charts & Research Termsheets Terminal
Permalink
Di., 07.04.2026       Azenta
US1143401024

BURLINGTON, Mass., April 7, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced the appointment of Trey Martin as President of its Multiomics business, effective April 6, 2026. In this role, Mr. Martin will lead the Multiomics organization and report to John Marotta, Azenta's President and Chief Executive Officer.This appointment is a...
Zur Nachricht
Azenta
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Di., 24.02.2026       Azenta
US1143401024

BURLINGTON, Mass., Feb. 24, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in Raymond James 47th Annual Institutional Investor Conference, on Tuesday March 3rd, 2026, which includes a presentation beginning at 4:00 pm ET. The live webcast can be accessed through the Azenta investor relatio...
Zur Nachricht
Azenta
Charts & Research Termsheets Terminal
Permalink
Mo., 09.02.2026       Azenta
US1143401024

BURLINGTON, Mass., Feb. 9, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced a strategic partnership with Frontier Space, a pioneer in commercial space-based research systems, to conduct cutting-edge scientific experiments in space. This collaboration aims to harness the unique benefits of the microgravity environment to accelerate...
Zur Nachricht
Azenta
Charts & Research Termsheets Terminal
Permalink
Mi., 21.01.2026       Azenta
US1143401024

BURLINGTON, Mass., Jan. 21, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal first quarter 2026 earnings which ended on December 31, 2025, on Wednesday, February 4, 2026, before the market opens.The Company will host a conference call and live webcast to discuss its financial results on the same day, Wednesday, February 4, 202...
Zur Nachricht
Azenta
Charts & Research Termsheets Terminal
Permalink
Mo., 29.12.2025       Azenta
US1143401024

BURLINGTON, Mass., Dec. 29, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that its affiliate, Azenta Germany GmbH, has signed a binding agreement for the sale of Azenta's B Medical Systems business to THELEMA S.À R.L., for a purchase price of US$63 million. The transaction is expected to close on or before March 31, 2026."The ag...
Zur Nachricht
Azenta
Charts & Research Termsheets Terminal
Permalink
Mi., 10.12.2025       Azenta
US1143401024

BURLINGTON, Mass., Dec. 10, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that its Board of Directors has approved a share repurchase program under which the company may repurchase up to $250 million of its outstanding common stock. The Repurchase Program is intended to enhance shareholder value and capitalize on undervaluation....
Zur Nachricht
Azenta
Charts & Research Termsheets Terminal
Permalink
Fr., 21.11.2025       Azenta
US1143401024

Q4'25 reported revenue growth of 6% year over year and 4% on an organic basisFY'25 reported revenue growth of 4% and 3% on an organic basisFY'25 Adjusted EBITDA margin expansion of 310 basis points versus last yearFY'26 organic revenue growth expected to be 3% to 5% year over year, with Adjusted EBITDA margin expansion of approximately 300 basis p...
Zur Nachricht
Azenta
Charts & Research Termsheets Terminal
Permalink
Mi., 12.11.2025       Azenta
US1143401024

BURLINGTON, Mass., Nov. 12, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal fourth quarter and full year 2025 earnings which ended on September 30, 2025, on Friday, November 21, 2025, before the market opens. The Company will host a conference call and live webcast to discuss...
Zur Nachricht
Azenta
Charts & Research Termsheets Terminal
Permalink
Di., 04.11.2025       Azenta
US1143401024

BURLINGTON, Mass., Nov. 4, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced a strategic partnership with the PRECEDE Foundation, an international, multi-institutional collaborative focused on early detection and prevention of pancreatic cancer. Azenta will provide secure storage of study samples i...
Zur Nachricht
Azenta
Charts & Research Termsheets Terminal
Permalink
Mi., 15.10.2025       Azenta
US1143401024

BURLINGTON, Mass., Oct. 15, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that it will host an Investor Day on Wednesday, December 10, 2025, at the Company's biorepository facility in Indianapolis, Indiana. This event will provide invited investors and analysts with a unique opportunity to gain...
Zur Nachricht
Azenta
Charts & Research Termsheets Terminal
Permalink
Do., 31.07.2025       Azenta
US1143401024

BURLINGTON, Mass., July 31, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that it has entered a collaboration with Frenova, a division of Fresenius Medical Care, and Nephronomics, a Renal Precision Medicine company, to begin genomic sequencing and data generation for Frenova's transformative MyReason® genomics research program....
Zur Nachricht
Azenta
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Mi., 30.07.2025       Azenta
US1143401024

BURLINGTON, Mass., July 30, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in the 10th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference, on Tuesday, August 12, 2025. About Azenta Life Sciences Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worl...
Zur Nachricht
Azenta
Charts & Research Termsheets Terminal
Permalink
Mi., 23.07.2025       Azenta
US1143401024

BURLINGTON, Mass., July 23, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal third quarter 2025 earnings which ended on June 30, 2025, on Tuesday August 5, 2025, before the market opens. The Company will host a conference call and live webcast to discuss its financial results on the same day, Tuesday, August 5, 2025, at 8:30...
Zur Nachricht
Azenta
Charts & Research Termsheets Terminal
Permalink
Di., 13.05.2025       Azenta
US1143401024

Integrated solution aims to reduce time and cost to lead candidates, advancing safer and more effective gene therapies to patients faster. BURLINGTON, Mass., May 13, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced a strategic partnership between GENEWIZ from Azenta Life Sciences, a global provider of multiomics and synthetic solu...
Zur Nachricht
Azenta
Charts & Research Termsheets Terminal
Permalink
Mi., 07.05.2025       Azenta
US1143401024

BURLINGTON, Mass., May 7, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the second quarter ended March 31, 2025. The results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, following the Company's announcement in the first fiscal quarter of 2025 of its intenti...
Zur Nachricht
Azenta
Charts & Research Termsheets Terminal
Permalink
Do., 24.04.2025       Azenta
US1143401024

BURLINGTON, Mass., April 24, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal second quarter 2025 earnings which ended on March 31, 2025, on Wednesday May 7, 2025, before the market opens. The Company will host a conference call and live webcast to discuss its financial results on the same day, Wednesday, May 7, 2025, at 8:30...
Zur Nachricht
Azenta
Charts & Research Termsheets Terminal
Permalink
Mo., 24.03.2025       Azenta
US1143401024

BURLINGTON, Mass., March 24, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced the publication of its annual Environmental, Social, & Governance ("ESG") report, highlighting the Company's ongoing commitment to advancing its strategy and actions aligned with key ESG priorities. The report includes ESG data for the Company's fisc...
Zur Nachricht
Azenta
Charts & Research Termsheets Terminal
Permalink
Mo., 10.03.2025       Azenta
US1143401024

BURLINGTON, Mass., March 10, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) announced that Lawrence Y. Lin, Executive Vice President and Chief Financial Officer, will participate in the Virtual KeyBanc Capital Markets Healthcare Forum on Wednesday, March 19, 2025, which includes a presentation beginning at 10:30 am ET. The live webcast can be a...
Zur Nachricht
Azenta
Charts & Research Termsheets Terminal
Permalink
Mi., 05.02.2025       Azenta
US1143401024

BURLINGTON, Mass., Feb. 5, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the first quarter ended December 31, 2024. The results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, following the Company's announcement in the fourth fiscal quarter of 2024 of its int...
Zur Nachricht
Azenta
Charts & Research Termsheets Terminal
Permalink
Do., 30.01.2025       Azenta
US1143401024

BURLINGTON, Mass., Jan. 30, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Dipal Doshi, Chief Executive Officer of Entrada Therapeutics (NASDAQ: TRDA) and a recognized leader in the biotechnology and pharmaceutical industries, has been elected to its Board of Directors at its Annual Meeting of Stockholders held earlier toda...
Zur Nachricht
Azenta
Charts & Research Termsheets Terminal
Permalink
Mo., 27.01.2025       Azenta
US1143401024

BURLINGTON, Mass., Jan. 27, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal first quarter 2025 earnings which ended on December 31, 2024, on Wednesday February 5, 2025, before the market opens. The Company will host a conference call and live webcast to discuss its financial results on the same day, Wednesday, February 5, 20...
Zur Nachricht
Azenta
Charts & Research Termsheets Terminal
Permalink
Do., 23.01.2025       Azenta
US1143401024

BURLINGTON, Mass., Jan. 23, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that it has been selected as the technology provider by UK Biocentre as they expand their large-scale sample storage in support of the preservation of internationally significant sample collections. This new system is in addition to the seven Azenta BioAr...
Zur Nachricht
Azenta
Charts & Research Termsheets Terminal
Permalink
Di., 19.11.2024       Azenta
US1143401024

NEW YORK, Nov. 19, 2024 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600: Flex Ltd (NASD: FLEX) will replace Azenta Inc. (NASD: AZTA) in the S&P MidCap 400, and Azenta will replace Envestnet Inc. (NYSE: ENV) in the S&P SmallCap 600 effective prior to the opening...
Zur Nachricht
Azenta
Charts & Research Termsheets Terminal
Permalink
Do., 14.11.2024       Azenta
US1143401024

BURLINGTON, Mass., Nov. 14, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in Stephens Annual Investment Conference, on Wednesday November 20, 2024, which includes a presentation beginning at 1:00 pm CT. The live webcast can be accessed through the Azenta investor relations website at htt...
Zur Nachricht
Azenta
Charts & Research Termsheets Terminal
Permalink
Di., 12.11.2024       Azenta
US1143401024

FY'24 revenue growth of 4%, reported and organic, in combined Sample Management Solutions and MultiomicsFY'25 organic revenue growth expected to be 3% to 5% year over year, with Adjusted EBITDA margin expansion of approximately 300 basis pointsPursuing a sale of B Medical Systems to simplify portfolio and drive revenue growth and profitabilityAnn...
Zur Nachricht
Azenta
Charts & Research Termsheets Terminal
Permalink
Mo., 04.11.2024       Azenta
US1143401024

BURLINGTON, Mass., Nov. 4, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal fourth quarter and full year 2024 earnings which ended on September 30, 2024, on Tuesday, November 12, 2024, after the market closes. The Company will host a conference call and live webcast to discuss its financial results on the same day, Tuesday, N...
Zur Nachricht
Azenta
Charts & Research Termsheets Terminal
Permalink
Mo., 04.11.2024       Azenta
US1143401024

William L. Cornog, Quentin Koffey and Alan J. Malus Add Deep Industry Expertise and Track Records of Shareholder Value Creation to the Board Establishes Value Creation Committee of the Board Comprised of New Directors, CEO John Marotta, and Current Director Martin Madaus Reaffirms Full-Year 2024 Financial Guidance BURLINGTON, Mass., Nov. 4, 2024...
Zur Nachricht
Azenta
Charts & Research Termsheets Terminal
Permalink
Mi., 30.10.2024       Azenta
US1143401024

BURLINGTON, Mass., Oct. 30, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced the launch of a long-read Whole Genome Sequencing (WGS) test for clinical applications. Azenta becomes the first commercial provider to obtain regulatory approval to offer this test in the United States.  Traditional short-read sequencing methods often st...
Zur Nachricht
Azenta
Charts & Research Termsheets Terminal
Permalink
Mi., 04.09.2024       Azenta
US1143401024

Succeeds Dr. Stephen Schwartz Following 14-Year Tenure BURLINGTON, Mass., Sept. 4, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) ("Azenta" or "the Company"), today announced that John P. Marotta will join the Company as President and CEO effective September 9, 2024, succeeding Dr. Stephen Schwartz, who is retiring following a distinguished ten...
Zur Nachricht
Azenta
Charts & Research Termsheets Terminal
Permalink
Mo., 12.08.2024       Azenta
US1143401024

BURLINGTON, Mass., Aug. 12, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that GENEWIZ Multiomics and Synthesis Solutions from Azenta Life Sciences will be hosting its 25th anniversary and the launch of its annual GENEWIZ Week event on September 16 - 20. GENEWIZ Week will showcase our commitment to providing cutting-edge soluti...
Zur Nachricht
Azenta
Charts & Research Termsheets Terminal
Permalink